Results 81 to 90 of about 29,535 (225)

Integration of Optical Genome Mapping in the Cytogenomic and Molecular Work‐Up of Hematological Malignancies: Expert Recommendations From the International Consortium for Optical Genome Mapping

American Journal of Hematology, Volume 100, Issue 6, Page 1029-1048, June 2025.
ABSTRACT The latest updates to the classification of hematolymphoid malignancies using the World Health Organization (WHO, 5th ed.) and ICC (International Consensus Classification) criteria highlight the critical need for comprehensive and precise cytogenomic data for diagnosis, prognostication, and treatment.
Rashmi Kanagal‐Shamanna, Anna Puiggros, Isabel Granada, Gordana Raca, Katrina Rack, Mar Mallo, Barbara Dewaele, Adam C. Smith, Yassmine Akkari, Brynn Levy, Robert P. Hasserjian, Adela Cisneros, Marta Salido, Guillermo Garcia‐Manero, Hui Yang, M. Anwar Iqbal, Ravindra Kolhe, Francesc Solé, Blanca Espinet   +18 more
wiley   +1 more source

Detection of a rare BCR–ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS) [PDF]

Proceedings of the National Academy of Sciences, 2012
Hypothesis directed proteomics offers higher throughput over global analyses. We show that immunoprecipitation (IP)–tandem mass spectrometry (LC-MS/MS) in H929 multiple myeloma (MM) cancer cells led to the discovery of a rare and unexpected BCR–ABL fusion, informing a therapeutic intervention using imatinib (Gleevec). BCR–ABL is the driving mutation in
Susanne B. Breitkopf, John M. Asara, John M. Asara, Min Yuan, German Pihan   +4 more
openaire   +2 more sources

Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients [PDF]

, 2017
More recently, alternative splicing of specific genes are investigated for their therapeutic potential. In particular, we reported the existence of BCR-ABL alternative splicing isoforms, in about 80% of Philadelphia-positive patients, which lead to the ...
Casnici C., Crotta K., Lattuada D., Marelli O., Mesiano G., Panuzzo C., Saglio G., Volpe G.   +7 more
core   +1 more source

BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors.

Blood, 1996
Chronic myelogenous leukemia (CML) is characterized by the t(9;22) translocation that results in chimeric genes encoding bcr/abl fusion proteins. Junction-spanning sequences represent unique tumor-specific moieties that might be exploited therapeutically.
Graham Pawelec, H. Max, T. Halder, O. Bruserud, A. Merl, P. D. Silva, Hubert Kalbacher   +6 more
semanticscholar   +1 more source

Autoinhibition of c-Abl [PDF]

, 2002
Despite years of investigation, the molecular mechanism responsible for regulation of the c-Abl tyrosine kinase has remained elusive. We now report inhibition of the catalytic activity of purified c-Abl in vitro, demonstrating that regulation is an ...
Dorey, Karel, Pluk, Helma, Superti-Furga, Giulio   +2 more
core   +1 more source

Molecular mechanisms in haematological malignancies [PDF]

, 2009
Haematopoiesis requires the constant production of large numbers of peripheral blood cells. This process is under tight control of transcription factor networks as well as cytokines, growth factors and hormones.
Avellino, Roberto, Grech, Godfrey, Schembri-Wismayer, Pierre   +2 more
core  

Adoptive Immunotherapy in Chimeras with Donor Lymphocytes [PDF]

, 2003
Allogeneic stem cell transplantation has a well-defined indication in the treatment of hematological malignancies. The beneficial immune effect of allogeneic marrow transplantation has long been known, but only recently have methods been developed to ...
Chen, Xiao, Guenther, Wolfgang, Kolb, Hans-Jochem, Ledderose, Georg, Roskrow, Marie, Schleuning, Michael, Schmid, Christoph, Weber, Martin, Woiciechowski, Anja   +8 more
core   +1 more source

Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia

Leukemia, 2013
Despite advances in allogeneic stem cell transplantation, BCR-ABL-positive acute lymphoblastic leukaemia (ALL) remains a high-risk disease, necessitating the development of novel treatment strategies.
M. Scherr, A. Elder, K. Battmer, D. Barzan, S. Bomken, M. Ricke-Hoch, A. Schro¨der, L. Venturini, H. Blair, J. Vormoor, O. Ottmann, A. Ganser, A. Pich, D. Hilfiker-Kleiner, O. Heidenreich, M. Eder   +15 more
semanticscholar   +1 more source

The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.

Blood, 2001
This report describes 2 patients with a clinical and hematologic diagnosis of chronic myeloid leukemia (CML) in chronic phase who had an acquired t(8;22)(p11;q11). Analysis by fluorescence in situ hybridization (FISH) and reverse transcription-polymerase
Asuman Demiroglu, E. Steer, C. Heath, K. Taylor, M. Bentley, S. L. Allen, P. Koduru, J. Brody, G. Hawson, R. Rodwell, Marylou Doody, F. Carnicero, A. Reiter, J. Goldman, J. Melo, Nicholas C. P. Cross   +15 more
semanticscholar   +1 more source

Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment

MedComm, Volume 6, Issue 6, June 2025.
Currently, a variety of methods such as flow cytometry, polymerase chain reaction, next‐generation sequencing, and other emerging methods are used for the detection of minimal residual disease, each of which has its own unique strengths and limitations and, more importantly, promising clinical applications.
Meiling Song, Wenjing Pan, Xinjie Yu, Jie Ren, Congli Tang, Zhu Chen, Zhe Wang, Yan Deng, Nongyue He, Hongna Liu, Song Li   +10 more
wiley   +1 more source